Zetagen Therapeutics Inc.
6 News & Press Releases found
Zetagen Therapeutics Inc. news
- Technology is a first-of-its kind molecular pathway designed to suspend cancer, inhibit pain, and regenerate bone
- Study will examine the safety and efficacy of ZetaMetTM in the treatment of metastatic bone lesions as part of advanced stage cancer therapy
- Study is targeting Stage 4 breast cancer patients who have metastatic lesions in their spinal vertebrae
Zetagen Therapeutics, a private, clinical-stage, biopharmaceutical company dedicated to dr
Jan. 18, 2022
- The technology is a first-of-its kind molecular pathway designed to suspend cancer, inhibit pain, and regenerate bone
- Zetagen Therapeutics is developing the therapy for patients living with metastatic bone lesions and other osteologic conditions
- The Company is targeting its first human clinical trial for metastatic bone lesions to begin in early 2022
Zetagen Therapeutics, a private, clinical-stage, biopharmaceutical company dedicated to driving break
Dec. 1, 2021
- U.S.-based biopharmaceutical company has discovered and patented a novel molecular pathway intended to treat metastatic bone lesions
- Latest patent issuance follows previous patents for methods in stimulating bone growth, promote controlled bone creation and repair of large segmental bone defects using ZetaMet™
- Company’s intellectual property pipeline targets other oncologic treatments for Skeletal- Related Events (SRE’s) and osteologic inter
Apr. 28, 2021
- U.S.-based biopharmaceutical company has discovered and patented a novel molecular pathway intended to treat metastatic bone lesions
- Latest patent issuance furthers the Company’s Global IP strategy
- Company’s intellectual property pipeline targets other oncologic treatments for Skeletal- Related Events (SRE’s) and osteologic interventions
private, clinical-stage, biopharmaceutical company dedicated to driving breakthrough inno
Jul. 23, 2020
- U.S.-based biopharmaceutical company has discovered and patented a novel molecular pathway intended to treat metastatic bone lesions
- Latest patent issuance follows previous patents for methods in stimulating bone growth using ZetaMet™
- New patent further enhances the Company’s Global IP strategy
Zetagen Therapeutics, Inc., a private, US-based biotechnology company dedicated to driving breakthrough innovation in the treatment of meta
Apr. 23, 2019